JP2009543788A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543788A5
JP2009543788A5 JP2009519562A JP2009519562A JP2009543788A5 JP 2009543788 A5 JP2009543788 A5 JP 2009543788A5 JP 2009519562 A JP2009519562 A JP 2009519562A JP 2009519562 A JP2009519562 A JP 2009519562A JP 2009543788 A5 JP2009543788 A5 JP 2009543788A5
Authority
JP
Japan
Prior art keywords
mucormycosis
composition
combination
item
antifungal agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009519562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/016065 external-priority patent/WO2008008537A2/en
Publication of JP2009543788A publication Critical patent/JP2009543788A/ja
Publication of JP2009543788A5 publication Critical patent/JP2009543788A5/ja
Pending legal-status Critical Current

Links

JP2009519562A 2006-07-13 2007-07-13 ムコール症および他の真菌性疾患を処置するための組成物および方法 Pending JP2009543788A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83109906P 2006-07-13 2006-07-13
US89762007P 2007-01-26 2007-01-26
US90407507P 2007-02-27 2007-02-27
PCT/US2007/016065 WO2008008537A2 (en) 2006-07-13 2007-07-13 Combi) compositions for the treatment of mucormycosis. comprising iron chelator and antifungal agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012258262A Division JP2013040212A (ja) 2006-07-13 2012-11-27 ムコール症および他の真菌性疾患を処置するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2009543788A JP2009543788A (ja) 2009-12-10
JP2009543788A5 true JP2009543788A5 (enExample) 2011-08-11

Family

ID=38610625

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009519562A Pending JP2009543788A (ja) 2006-07-13 2007-07-13 ムコール症および他の真菌性疾患を処置するための組成物および方法
JP2012258262A Pending JP2013040212A (ja) 2006-07-13 2012-11-27 ムコール症および他の真菌性疾患を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012258262A Pending JP2013040212A (ja) 2006-07-13 2012-11-27 ムコール症および他の真菌性疾患を処置するための組成物および方法

Country Status (18)

Country Link
US (1) US20100129434A1 (enExample)
EP (2) EP2043636A2 (enExample)
JP (2) JP2009543788A (enExample)
KR (1) KR20090036587A (enExample)
AU (1) AU2007272781B2 (enExample)
BR (1) BRPI0714221A2 (enExample)
CA (1) CA2657634A1 (enExample)
CL (1) CL2007002026A1 (enExample)
IL (1) IL196389A0 (enExample)
MA (1) MA30625B1 (enExample)
MX (1) MX2009000506A (enExample)
NO (1) NO20090565L (enExample)
NZ (1) NZ574862A (enExample)
RU (1) RU2464024C2 (enExample)
SG (1) SG177122A1 (enExample)
TN (1) TN2009000004A1 (enExample)
TW (1) TWI448285B (enExample)
WO (1) WO2008008537A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33199B1 (fr) * 2009-03-19 2012-04-02 Los Angeles Biomed Res Inst Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
CA2885394A1 (en) * 2012-11-12 2014-05-15 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferipone
WO2014120774A1 (en) 2013-01-29 2014-08-07 Case Western Reserve University Fungal iron acquisition inhibitors and uses thereof
US20160199361A1 (en) * 2013-08-19 2016-07-14 Rutgers, The State University Of New Jersey Method of Inducing An Anti-Retroviral Immune Response By Counter-Acting Retro-Virus Induced Anti-Apoptosis
WO2016025559A1 (en) * 2014-08-13 2016-02-18 Zoneone Pharma, Inc. Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems
US20170231910A1 (en) * 2014-08-13 2017-08-17 Mark E. Hayes Pharmaceutical formulations of chelating agents as a metal removal treatment system
US11298364B2 (en) * 2015-08-31 2022-04-12 The University Of Adelaide Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins
WO2017197386A1 (en) * 2016-05-13 2017-11-16 The Brigham And Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of mucorales fungi
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
WO2020264076A1 (en) 2019-06-28 2020-12-30 The Procter & Gamble Company Light augmented treatment method
JP2023057423A (ja) * 2021-10-11 2023-04-21 国立大学法人 熊本大学 ムコール症治療薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
TW349870B (en) * 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
DE50111949D1 (de) * 2000-12-16 2007-03-15 Alstom Technology Ltd Komponente einer Strömungsmaschine
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
ITMI20022447A1 (it) * 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
TW200503781A (en) * 2002-12-31 2005-02-01 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
WO2004108114A2 (en) * 2003-03-31 2004-12-16 Dinesh Shantilal Patel Anti-fungal composition and a process for its manufacture
DE10356409B4 (de) * 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh Neues Arzneimittel Oxachelin und Derivate

Similar Documents

Publication Publication Date Title
JP2009543788A5 (enExample)
CA2657634A1 (en) Compositions and methods for the treatment of mucormycosis and other fungal diseases
Rauseo et al. Hope on the horizon: novel fungal treatments in development
US9169290B2 (en) Peptides and their use
RU2009137946A (ru) Производные пиридазинона для применения в качестве ингибиторов глюкансинтазы
Fortún et al. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high‐risk liver transplantation recipients: a propensity score analysis
McCarthy et al. Clinical pharmacokinetics and pharmacodynamics of isavuconazole
JP2018021060A5 (enExample)
IL275121B1 (en) Antifungal agents History of pyridine derivatives transformed into heterocycles
Farowski et al. Posaconazole: a next-generation triazole antifungal
PH12019500638A1 (en) Composite formed into single layer, comprising candesartan and amlodipine
MX2007010703A (es) Composiciones antifungicas.
Phoompoung et al. Treatment of non-aspergillus mold infections: a focus on mucormycosis and fusariosis
JP2011518228A5 (enExample)
JP2008540453A5 (enExample)
Ramos et al. Prospective Medicines against the Widespread, Emergent, and Multidrugresistant Opportunistic Fungal Pathogen Candida auris: A Breath of Hope
JP2016531886A5 (enExample)
PROFILE ECB, LY 303366, V-echinocandin, VEC, VER 002, VER-02
McCreary et al. Isavuconazole: Has it saved us? A pharmacotherapy review and update on clinical experience
Ramos-Martín et al. Ravuconazole
Weigand et al. Antifungal therapy in surgical ICU patients
HK1201726A1 (en) Treatment method for steroid responsive dermatoses
R Varughese et al. Emergence of azole therapy for cancer associated fungal infections and their potential Human toxicity
Mellado et al. Head-to-Head Comparison of the Activities
Crofskey Posaconazole prophylaxis proves promising